» Articles » PMID: 34401606

Germline ATM Mutation and Somatic PIK3CA and BCOR Mutations Found in an Infant with Aggressive Orbital Embryonal Rhabdomyosarcoma

Overview
Specialty Ophthalmology
Date 2021 Aug 17
PMID 34401606
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To report a case of aggressive infantile orbital embryonal rhabdomyosarcoma harboring germline ATM mutation and 2 somatic mutations as revealed by next-generation sequencing and the potential application for personalized therapy.

Observations: A 7-month-old male developed a rapidly progressive left proptosis over 6 weeks due to a large medial orbital mass. Biopsy revealed embryonal rhabdomyosarcoma. After the first cycle of chemotherapy, re-imaging showed interval tumor enlargement with intracranial extension. Craniotomy, combined with orbital exenteration, was performed. Tumor specimens and blood samples were sent for 596 gene DNA sequencing panels with RNA-sequencing focused on actionable mutations as well as gene fusion detection. Sequencing revealed 3 clinically relevant mutations: a germline ATM loss-of-function (LOF) mutation, a somatic PIK3CA gain-of-function mutation, and a somatic BCOR LOF mutation. No chromosomal translocation was detected. Workup for metastasis was positive for bone marrow involvement. Despite standard high-dose adjuvant chemotherapy in combination with radiation therapy, the patient died 10 months later with metastatic diseases.

Conclusions And Importance: This case highlights an aggressive form of embryonal rhabdomyosarcoma in an infantile orbit. The presence of germline mutation may explain the increased chemo-resistance and adverse prognosis, and may be used as the target for genomic-directed therapy.

References
1.
Ahmed M, Rahman N . ATM and breast cancer susceptibility. Oncogene. 2006; 25(43):5906-11. DOI: 10.1038/sj.onc.1209873. View

2.
Takagi M, Ogawa C, Aoki-Nogami Y, Iehara T, Ishibashi E, Imai M . Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol. BMC Pediatr. 2019; 19(1):31. PMC: 6347807. DOI: 10.1186/s12887-019-1409-7. View

3.
Joshi D, Anderson J, Paidas C, Breneman J, Parham D, Crist W . Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2004; 42(1):64-73. DOI: 10.1002/pbc.10441. View

4.
Arafeh R, Samuels Y . PIK3CA in cancer: The past 30 years. Semin Cancer Biol. 2019; 59:36-49. DOI: 10.1016/j.semcancer.2019.02.002. View

5.
Hawkins D, Gupta A, Rudzinski E . What is new in the biology and treatment of pediatric rhabdomyosarcoma?. Curr Opin Pediatr. 2013; 26(1):50-6. PMC: 4096484. DOI: 10.1097/MOP.0000000000000041. View